Historical Stock Chart
2 Months : From Oct 2019 to Dec 2019
By Colin Kellaher
AstraZeneca PLC (AZN, AZN.LN) on Monday said the U.S. Food and Drug Administration approved Farxiga to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes.
The U.K. drug maker said Farxiga is the first sodium-glucose cotransporter 2 inhibitor approved in the U.S. to reduce the risk of hospitalization for heart failure in type 2 diabetes patients with established cardiovascular disease or multiple cardiovascular risk factors.
The FDA nod follows an update to Farxiga's marketing authorization in the EU in August. The drug is also under regulatory review in China, with a decision anticipated in the first half of 2020, AstraZeneca said.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
October 21, 2019 07:38 ET (11:38 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.